Loading
A phase 3 trial of Serplulimab, Atezolizumab in small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC is a phase 3 interventional study registered as NCT05468489 by Shanghai Henlius Biotech, with 200 participants planned, started 2022-11-18 and due to reach its primary completion in 2026-02-28. Interventions recorded: Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide). Conditions listed: Extensive Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.